With more than one million users globally, mySugr is one of the leading mobile diabetes platforms, which will become an integral part of Roche’s new patient-centred digital health services platform in diabetes care. Through this acquisition, Roche will expand its leading position in the area of diabetes management. The transaction was announced on 30 June 2017.
"Healthcare is a growing and increasingly important sector on which Schoenherr places a lot of emphasis. As the partner responsible for this industry within our firm, I was particularly excited to support Roche on this transaction," stated Schoenherr corporate m&a partner Florian Kusznier.
Founded in 2012, mySugr specialises in all-around care for people with diabetes. Its apps and services combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and seamless integration with a growing number of medical devices.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics.
The Schoenherr team advising Roche as lead counsel was headed by Florian Kusznier (partner, corporate/m&a) and Clemens Rainer (attorney at law, corporate/m&a). They were supported by Günther Leissler (counsel, regulatory, newTech); Veronika Wolfbauer (attorney at law, regulatory, newTech); Dominik Hofmarcher (attorney at law, ip, it & life sciences); Julia Wasserburger (attorney at law, corporate/m&a); Mario Perl (attorney at law, tax); Marco Thorbauer (associate, tax); Teresa Waidmann (associate, labour & employment); Arzu-Sema Cakmak (associate, corporate/m&a); Christopher Jünger (associate, corporate/m&a); Sascha Smets (associate, corporate/m&a); and Volker Weiss (partner, eu & competition).